Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.77 |
| ▸ | ADA | P00813 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | NT5E | P21589 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | AHCY | P23526 | 2/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137892 | 0.89 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL10169502 | 0.89 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL873738 | 0.89 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL15908433 | 0.89 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL474849 | 0.89 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL14589609 | 0.89 | ADORA2A (0.80) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL4845331 | 0.88 | LMNA (0.64) | ADORA2AADALMNANT5EHIF1A | |
| SCHEMBL29848577 | 0.88 | ADORA2A (0.78) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL28952403 | 0.88 | ADORA2A (0.78) | ADORA2AADAADORA3ADORA1ADORA2B | |
| SCHEMBL28484259 | 0.87 | ADORA2A (1.00) | ADORA2AADALMNANT5EADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476169-A4 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | MERCK & CO INC (US) | 2009-06-03 | — | — | EP | claimed |
| US-7323453-B2 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | claimed |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | claimed |
| EP-1476169-A1 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | Merck & Co., Inc. (US) | 2004-11-17 | — | — | EP | claimed |
| WO-2003068244-A1 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | MERCK & CO., INC. (US) | 2003-08-21 | — | — | WO | claimed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| EP-1476169-A4 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | MERCK & CO INC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7323453-B2 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323453-B2 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323453-B2 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK & CO., INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | disclosed |
| EP-1476169-A1 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | Merck & Co., Inc. (US) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068244-A1 | METHODS OF INHIBITING ORTHOPOXVIRUS REPLICATION WITH NUCLEOSIDE COMPOUNDS | MERCK & CO., INC. (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | ADORA2A 71/4885ADA 18/4885LMNA 982/4885 |
| US-20050164960-A1 | Methods of inhibiting orthopoxvirus replication with nucleoside compounds | ITPA, PNP, NUDT1 | ADORA2A 192/4885ADA 43/4885LMNA 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.